FAQs for NIBIB’s COVID-19 NOSIs

Applicants must hold an active NIBIB grant or cooperative agreement.

Competitive Revisions: Eligible activity codes for emergency competitive revision applications to PA-20-135 are limited to the following mechanisms: DP1, DP2, P41, R00, R01, R03, R15, R21, R24, R37, R41, R43, R44, R56, U01, U18, U24, U2C, U54, UG3, UH2, UH3. 

Administrative Supplements: A list of eligible activity codes for administrative supplements can be found at PA-18-591

A Competitive Revision is a request for an increase in support in a current budget period for an expansion of the project’s scope.

An Administrative Supplement provides additional funding to a currently funded grant to meet increased costs that are within the scope of the approved project.

A change in scope is a change in the direction, aims, objectives, purposes, or type of research training, identified in the approved project.

Potential indicators of a change in scope include, but are not limited to, the following:

• Change in the specific aims approved at the time of award.
• Substitution of one animal model for another.
• Change from the approved use of live vertebrate animals.
• Change from the approved involvement of human subjects.

For details please refer to Section 8.1.2.5 of NIH Grants Policy Statement (PDF)

Please contact the NIBIB small business program specialists:

Todd Merchak

NIBIB/ESP/OPESP

301-496-8592

NIBIB-SBIR@mail.nih.gov

Ilana Goldberg, PhD

NIBIB/DDST

301-402-3465

NIBIB-SBIR@mail.nih.gov

Yes, pre-award authority may be used by awardees. Pre-award spending is always done at the recipient’s own risk. As an example, if a grant is issued in August, then under normal policy, the grantee can charge expenses to the grant that occurred within the previous 90 days, (i.e. since May). However, NIH has extended pre-award authority to Jan 20, 2020. See NOT-OD-20-086 allowing reimbursement prior to the standard 90-day period for all recipients affected by COVID-19. Documentation should be provided to the GMS.

Funding announcements include the current NIBIB SBIR funding mechanisms:

• PA-19-270 - PHS 2019-02 Omnibus Solicitation of the NIH Small Business Technology Transfer Grant Applications (Parent STTR [R42/R42] Clinical Trial Not Allowed)
• PA-19-272 - PHS 201-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
• PA-18-631 - NIBIB Exploratory Clinical Trials for Small Businesses ([R44] Clinical Trial Required)

SBIR grants will go through the normal review process and therefore will be reviewed according to the stated review criteria in the NOFO. As always, applications will be administratively reviewed for NIBIB mission fit. Applicants are strongly encouraged to contact their Program Director prior to submitting an application.

Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents.

• PA-19-056 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
• PA-18-418 - NIBIB Research Project Grant (R01 Clinical Trial Required)
• PAR-18-530 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
• PAR-20-155 - Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
• PAR-20-084 - NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
• PAR-18-433 - NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)
• PA-19-053 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
• PA-19-052 - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)